Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 5/20 | 0.42 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 2/20 | 0.38 |
| ▸ | DDX3X | O00571 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 3/20 | 0.38 |
| ▸ | F10 | P00742 | 3/20 | 0.38 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.38 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.38 |
| ▸ | F7 | P08709 | 3/20 | 0.38 |
| ▸ | F3 | P13726 | 3/20 | 0.38 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.38 |
| ▸ | GRM5 | P41594 | 2/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.37 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13104997 | 0.90 | KAT2B (0.44) | ACACBLRRK2NAMPT | |
| SCHEMBL13994031 | 0.83 | ACACB (0.40) | ACACBIRAK4EGFRDDX3XF2 | |
| SCHEMBL13996482 | 0.83 | ACACB (0.40) | ACACBIRAK4DDX3XF2F10 | |
| SCHEMBL7760091 | 0.81 | LRRK2 (0.43) | ACACBGRM5LRRK2 | |
| SCHEMBL21443397 | 0.81 | LRRK2 (0.43) | ACACBGRM5LRRK2 | |
| SCHEMBL13993826 | 0.81 | LRRK2 (0.43) | ACACBGRM5LRRK2 | |
| SCHEMBL28446956 | 0.80 | ACACB (0.51) | ACACBEGFRGRM5NAMPT | |
| SCHEMBL28446957 | 0.80 | ACACB (0.51) | ACACBEGFRGRM5NAMPT | |
| SCHEMBL17361821 | 0.80 | CARM1 (0.40) | ACACB | |
| SCHEMBL2226844 | 0.79 | AKT1 (0.40) | ACACBIRAK4LRRK2SLC5A1SLC5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100273842-A1 | AMINE DERIVATIVES HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY AND THE USES THEREOF | SHIONOGI & CO., LTD. (JP) | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273842-A1 | AMINE DERIVATIVES HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY AND THE USES THEREOF | NPY5R, NPY1R, NPY2R | ACACB 1989/4885IRAK4 3959/4885IDO1 326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.